tirzepatide manufacturer eli lilly could launch obesity drug in India next year, CEO says Eli Lilly's weight loss drug
Description
When administered via subcutaneous injection, these medications bind to GLP-1 receptors in multiple tissues throughout the body, including the pancreas, brain, and gastrointestinal tract
This area is often preferred by people who find the abdomen more sensitive
Speak with a PlexusDx consultant to explore payment options and ensure coverage eligibility
Learn about our GLP-1 program, find out if youre a candidate, and start treatment the same day
Photograph your progress monthly
